A phase 2B long-term, randomized, open-label, safety and tolerability trial comparing [S,S]-reboxetine (PNU-165442G) with routine care in patients with postherpetic neuralgia (PHN)

Trial Profile

A phase 2B long-term, randomized, open-label, safety and tolerability trial comparing [S,S]-reboxetine (PNU-165442G) with routine care in patients with postherpetic neuralgia (PHN)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2007

At a glance

  • Drugs Esreboxetine (Primary)
  • Indications Postherpetic neuralgia
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Nov 2007 Status changed from in progress to discontinued. The study was stopped due to business/operational issues.
    • 10 Oct 2007 Status changed from recruiting to in progress.
    • 27 Jan 2007 New trial centre added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top